Latest News

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer
Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

June 1st 2025

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer
T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer

May 31st 2025

PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer
PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer

May 31st 2025

Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors
Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

May 31st 2025

Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC
Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC

May 31st 2025

More News